2021-01-07,Apellis Announces Agreements to Exchange Approximately $107.5 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
2021-01-05,Apellis Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020-12-28,Apellis' (APLS) Pipeline Candidate Pegcetacoplan Promising
2020-12-10,Apellis and Sobi Report Positive Top-line Results at 48 Weeks from the Phase 3 PEGASUS Study of Pegcetacoplan in PNH
2020-12-07,Apellis Reports Pegcetacoplan Demonstrates Greater Treatment Responses and Quality-of-Life Improvements Compared to C5 Inhibitors for PNH
2020-12-04,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-11-30,Apellis Pharmaceuticals to Present at the 2020 Evercore ISI HealthCONx Conference
2020-11-20,Apellis (APLS) Begins Dosing With Pegcetacoplan in ALS Study
2020-11-19,Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan
2020-11-17,Apellis' (APLS) Blood Disorder Drug Gets FDA's Priority Tag
2020-11-16,Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNH
2020-11-13,Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual
2020-11-11,Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2020-11-05,Apellis to Present New Data Supporting the Efficacy and Safety of Pegcetacoplan in PNH at the American Society of Hematology Annual Meeting
2020-11-03,Apellis Pharmaceuticals' (APLS) Q3 Loss Wider Than Expected
2020-11-03,Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Too Much Debt?
2020-11-02,Apellis Pharmaceuticals Reports Third Quarter 2020 Financial Results
2020-10-27,Oppenheimer: These 3 Stocks Are Poised to Surge by at Least 60%
2020-10-27,Apellis and Sobi Enter Collaboration for Global Co-development and Ex-US Commercialization of Systemic Pegcetacoplan in Rare Diseases with Urgent Need for New Treatments
2020-10-19,Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan  in Patients with Geographic Atrophy (GA)
2020-10-15,Apellis Announces New Data Demonstrating Correlation between Complement Activation and COVID-19 Severity
2020-10-09,Apellis to Present Positive Results from the Phase 2 DISCOVERY Study of Pegcetacoplan in C3 Glomerulopathy (C3G) at ASN Kidney Week
2020-10-07,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-10-05,"Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet Need"
2020-10-03,Apellis Announces New Analysis Demonstrating Targeted C3 Therapy Pegcetacoplan Slows Progression of Early Disease in Patients with Geographic Atrophy (GA)
2020-09-24,Apellis Pharmaceuticals to Present at Stifels 2020 Immunology and Inflammation Virtual Summit
2020-09-21,Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA) at EURETINA 2020
2020-09-16,"Apellis Pharmaceuticals, Inc. (APLS): Hedge Funds Taking Some Chips Off The Table"
2020-09-16,Apellis Submits Pegcetacoplan Applications to FDA and EMA
2020-09-15,Apellis Announces Submission of Pegcetacoplan Marketing Applications to FDA and EMA for Patients with PNH
2020-09-04,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-09-02,Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2020-09-01,"Benzinga's Top Upgrades, Downgrades For September 1, 2020"
2020-08-30,"Why Is Apellis Pharmaceuticals, Inc. (APLS) Down 3.8% Since Last Earnings Report?"
2020-08-21,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-08-07,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-07-31,Apellis Pharmaceuticals Reports Second Quarter 2020 Financial Results
2020-07-13,"Did Hedge Funds Make The Right Call On Apellis Pharmaceuticals, Inc. (APLS) ?"
2020-07-07,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-07-07,"Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)"
2020-07-02,Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
2020-06-16,Apellis Pharmaceuticals to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
2020-06-12,CRISPR Rally: The First Gene-Editing Drug Continues To Show Promise
2020-06-12,"Hedge Funds Are Selling Apellis Pharmaceuticals, Inc. (APLS)"
2020-06-12,Shares of Apellis rise on clinical data for rare blood disease drug
2020-06-12,"New Pivotal Data Demonstrate Superiority of Apellis Pegcetacoplan to Eculizumab in Improving Hemoglobin Levels, Independent of Prior Transfusions, in PNH"
2020-06-10,Apellis Announces Investor Conference Call to Discuss Phase 3 PEGASUS Data to be Presented at the 25th Annual Congress of the European Hematology Association (EHA)
2020-06-05,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-06-04,Apellis Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
2020-05-29,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-05-28,Apellis Initiates Phase 1/2 Study of APL-9 in Patients with Severe COVID-19
2020-05-21,Apellis Announces Plans to Submit NDA for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH)
2020-05-14,Apellis to Present Pivotal Paroxysmal Nocturnal Hemoglobinuria (PNH) Data at 25th EHA Annual Congress
2020-05-08,Apellis Pharmaceuticals to Present at the BofA Securities 2020 Health Care Conference
2020-05-07,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-05-07,Apellis Pharmaceuticals Announces Private Placement of Convertible Senior Notes
2020-04-29,Apellis Pharmaceuticals Reports First Quarter 2020 Financial Results
2020-04-28,Apellis Reports Analysis from Phase 1b Geographic Atrophy Study
2020-04-07,"Hedge Funds Have Never Been This Bullish On Apellis Pharmaceuticals, Inc. (APLS)"
2020-04-07,Why Apellis Pharmaceuticals (APLS) Stock Might be a Great Pick
2020-04-06,Paul Fonteyne Joins Apellis Board of Directors
2020-02-27,Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-26,Apellis Pharmaceuticals to Present at the 40th Annual Cowen Health Care Conference
2020-02-06,"CEO council reveals innovation center location, plans international summit"
2020-01-16,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-01-15,"Alexion pushes 'high-risk, high-reward' ALS strategy amid competitive pressure"
2020-01-13,Apellis Pharmaceuticals' stock offering closes $50M higher than expected
2020-01-13,Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
2020-01-13,"Apellis Pharmaceuticals, Inc. (APLS) vs. Hedge Fund Favorites in 2019"
2020-01-09,Apellis Pharmaceuticals is planning to raise $350M  here's how
2020-01-08,Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2020-01-08,"Biotech Stock Roundup: Updates From INCY & EXEL, APLS & LIFE Surge on Positive Data"
2020-01-08,"The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results"
2020-01-08,Apellis' (APLS) PNH Drug Betters Alexion's Soliris in Study
2020-01-07,This Biotech Just Topped Alexion's Biggest Moneymaker  And Rocketed
2020-01-07,Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock
2020-01-07,Publicly traded company moves HQ out of Louisville area
2020-01-07,"Can a Drug's $500,000 Price Withstand Competition?"
2020-01-07,Apellis Stock Soars After Head-to-Head Drug Trial Vs Alexion
2020-01-07,Waltham biotech's drug bests Alexion's blockbuster Soliris in new trial
2020-01-07,Apellis stock soars on positive data for potential Soliris competitor
2020-01-07,Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
2020-01-07,Apellis Pharmaceuticals Soars as Blood-Drug Test Outperforms Alexion's Therapy
2020-01-02,Apellis Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
2019-12-09,Are Options Traders Betting on a Big Move in Apellis Pharmaceuticals (APLS) Stock?
2019-12-06,"Hedge Funds Have Never Been This Bullish On Apellis Pharmaceuticals, Inc. (APLS)"
2019-11-26,Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
2019-11-15,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-11-08,Apellis Presents First Data on APL-2 in C3 Glomerulopathy at ASN Kidney Week
2019-11-07,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-11-05,Apellis Pharmaceuticals Reports Third Quarter 2019 Business Update and Financial Results
2019-10-28,"Is Apellis Pharmaceuticals, Inc. (APLS) Going to Burn These Hedge Funds?"
2019-10-16,Alexion makes $930M acquisition in bid to bolster blockbuster drug
2019-10-11,Apellis to Present Data on APL-2 in Complement 3 Glomerulopathy at ASN Kidney Week 2019
2019-10-04,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-10-03,Apellis Pharmaceuticals (APLS) Catches Eye: Stock Jumps 5.2%
2019-09-27,Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2019-09-26,Apellis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
2019-09-18,Phase 2 Study Published in Ophthalmology Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to Age-Related Macular Degeneration
2019-09-16,Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes
